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Abstract 
BACKGROUND: Adverse reactions to intravenous immunoglobulins (IVIG) are divided by organ system involved, 
or by timing of onset–immediate which occur during infusion usually rate-related, true IgE-mediated anaphylaxis 
and delayed reaction which occur hours to days after the infusion.  
AIM: To describe the adverse events of patients given IVIG infusions. 
METHODS: Total number of patients receiving IVIG was 41 with 25 males (60.97%) and 16 females (39.02%), 
age 2 months-35 years. A total number of infusions was 1350. 
RESULTS: Total number of adverse reactions 15, 14 patients with immediate-type and 1 with delayed type. Total 
percentage of adverse reactions in a given sample was 1.1% of all IVIG infusions. Fever was the most common 
immediate type of reaction occurring in 11 patients (78.57%) followed by acrocyanosis 10 patients (71.42%), skin 
rash 9 patients (64.28%) and headache 8 patients (57.14). Delayed-type of reactions (like fever, headache and 
vomiting) was present in one patient. Majority of the adverse effects occurred at the infusion rate higher than 1, 5 
ml/kg/hour, which is still within recommended speed. 
CONCLUSION: About 1.1% of IVG infusions where with adverse events. Most common manifestations where: 
fever, acrocyanosis, skin rash and headache, which occurred 1-6 hours from the beginning of the infusion. The 
occurrence of adverse reactions to IVIG was related to the infusion rates in a fashion that faster infusion rate 
gives more reactions. Adverse reactions were managed by reduction of the infusion rate and administration of 
medications such as paracetamol, antihistamines and steroids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Intravenous immunoglobulins (IVIG) are the 
preparation of highly purified IgG derived from large 
pools of human plasma via ethanol fractionation. 
Preparations are stabilised using substances such as 
human albumin, glycine, polyethene glycol, or sugars 
such as sucrose, maltose or glucose. Intravenous 
immunoglobulins are mainly used as replacement 
therapy for immunodeficiency, and immunomodulatory 
therapy in autoimmune and inflammatory conditions 
[1], [2], [3]. These preparations are manufactured by 
different companies and are at the disposal of the 
clinician. As a result of preparation processes 
reactions may occur to either the immunoglobulin, 
aggregates the preparation or the stabilising agent [5]. 
Possible adverse effects of IVIG may be 
divided by organ system or by timing of onset, i.e., 
immediate or delayed. Immediate reactions occur 
during the infusion, and include rate-related reactions, 
true immunoglobulin E (IgE)-mediated anaphylaxis (in 
immunoglobulin A (IgA)-deficient patients), and 
reactions related to concurrent infection [4], [7], [8], 
[9], [10], [11], [12]. Delayed reactions generally occur 
hours to days after the infusion [13], These can be a 
headache, aseptic meningitis, acute kidney injury, 
hemolysis, venous thrombosis, myocardial infarction, 
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transient ischemic attacks, and stroke. Some of these, 
particularly thrombotic events, may also occur during 
infusions [14]. These adverse events may be due to 
the relative "impurity" of the commercial preparations, 
or the undesirable effects of its active component 
immunoglobulin G (IgG). The most common adverse 
effects occur soon after infusions and can include a 
headache, flushing, chills, myalgia, wheezing, 
tachycardia, lower back pain, nausea, and 
hypotension [4], [7], [8], [9], [10], [11], [12]. 
Intravenous immunoglobulin is a biological product, 
and potentially important product-manufacturing 
differences may exist. It is perhaps for this reason that 
adverse effects appear to vary considerably among 
different IVIG preparations available in the market [5], 
[6].  
This study aims to determine the incidence 
and type of adverse events following the infusion of 
different IVIG preparations. Understanding the 
common side effects and the IVIG preparations are 
important in caring for patients receiving IVIG. 
 
 
Methods 
 
This is a retrospective study. Records of 
patients given IVIG at the ward and the outpatient 
department from January 2006 to January 2016 at 
Immunology department of Pediatric Hospital-Skopje 
were reviewed. Demographic data such as age, sex, 
indication for IVIG treatment were taken from the 
charts of the patients. Total of 41 patients receives 
IVIG preparations, 25 males (60.97%), 16 females 
(39.02%), age 2 months -35 years, with a total 
number of infusions 1350. Indication for IVIG 
treatment and dosage where as follows: 18 patients 
with primary immunodeficiency 400 mg/kg/monthly, 5 
patients with Kawasaki syndrome 400 
mg/kg/5doses/daily, 10 patients with sepsis 400 
mg/kg/dose/1-2 times divided by 2 days, 3 patients 
with atopic dermatitis and transient infantile 
hypogammaglobulinemia 400 mg/kg/monthly/6monts, 
2 patients with transient infantile 
hypogammaglobulinemia and recurrent infections 400 
mg/kg/monthly/6months and 5 patients with ITP 400 
mg/kg/5doses/daily. The rate of IVIG infusions was 
0.5 ml/kg/hour and increased every 15-30 min, based 
on the patient's tolerance up to 3 ml/kg/hour. IVIG 
preparation used was Kiovig- Baxter (glycin as a 
stabiliser) IgVena-Kedrion (sucrose as a stabiliser) 
Octogam-Octapharma (maltose as a stabiliser).  
Once patients with adverse reactions have 
been identified, the following data were taken and 
reviewed: a specific type of adverse reaction to IVIG; 
the time interval between onset of adverse reaction 
and beginning of IVIG infusion and appearance of 
adverse reactions; IVIG preparation, dose and 
infusion rate; and medical management did during the 
adverse event. Statistics were used to analyse and 
interpret the data. 
 
 
Results 
 
A total number of patients receiving IVIG was 
41 [25 males (60.97%), 16 females (39.02)] with age 2 
months to 35 years. A total number of infusions was 
1350. Total numbers of adverse reactions were 15, 14 
patients with immediate-type and 1 with delayed type. 
Total percentage of adverse reactions in a given 
sample was 1.1% of all IVIG infusions. Immediate-
type of reactions were: Fever was the most common 
immediate type of reaction occurring in 11 patients 
(78.57%) followed by acrocyanosis 10 (71.42%) and 
skin rash 9 (64.28%), followed by headache 8 
(57.14%)shortness of breath 6 (42.85%), perioral 
cyanosis 6 (42.85), hypotension 5 (35.71) and chest 
pain 3 (21.42%), (Table 1). 
Table1: Immediate adverse reactions to IVIG 
Symptoms Number of patients (%) 
Fever 11 (78.57) 
Acrocyanosis 10 (71.42) 
Skin rash 9 (64.28) 
A headache 8 (57.14) 
Perioral cyanosis 6 (42.82) 
Shortness of breath 6 (42.82) 
Hypotension 5 (35.71) 
Chest pain 3 (21.42) 
 
Delayed types of reaction were a headache, 
fever and vomiting in one patient (6.6%), (Table 2). 
Table 2: Delayed adverse reactions to IVIG 
Symptoms No of patients 
Vomiting 1 
Fever 1 
A headache 1 
 
Time of onset from the beginning of the 
infusion: 0-30 min 7 patients, 30 min to 1 hour 5 
patients, 1 hour to 6 hours 2 patients, 24 hours 1 
patient, (Table 3). 
Table 3: IVIG infusions and time of onset of adverse reactions 
Time from the beginning of the infusion Frequency 
0-30 min 7 
30-60 min 5 
60 min- 6hours 2 
24 hours 1 
 
Symptoms were affected by fast infusion 
rates, the faster the infusion rate, the more adverse 
reactions occur. In our study, most of the adverse 
effects occurred at the infusion rate higher than 1, 5 
ml/kg/hour, which is still within the recommended 
speed. There was notable difference in frequency of 
adverse reactions depending on the brand of IVIG 
used for infusion (Figure 1). 
 Reactions were managed by reducing the 
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rate of infusion and giving of medications such as 
paracetamol, antihistamines and steroids. 
 
Figure 1: Adverse reactions of IVIG per brand 
  
 
 
Discussion 
 
The pathogenesis of adverse reactions of 
IVIG is still unknown. IVIG preparations differ in their 
composition and properties, and these can contribute 
to its efficacy and tolerability [5], [6]. Major 
determinants are immunoglobulins, particularly IgA 
content, sodium content, sugar content and osmolality 
[6]. The most common adverse reactions of IVIG in 
our study are the immediate type, occur in the first 30-
60 min of administration. This includes fever, chills, 
headache, skin rash and even some vasomotor and 
cardiovascular manifestations marked by changes in 
blood pressure, tachycardia and cyanosis. These 
reactions are most common [4], [7], [8], [9], [10], [11], 
[12] and probably are results from aggregated 
immunoglobulin molecules which cause the 
complement system to be activated, antigen-antibody 
reactions, possible contaminants or even stabilizers 
that may have been used during the manufacturing 
process. Symptoms were affected by fast infusion 
rates, faster the infusion rate more adverse reactions 
occur. In our study, most of the adverse effects 
occurred at the infusion rate higher than 1, 5 
ml/kg/hour, which is still within the recommended 
speed. Delayed types of reaction were a headache, 
fever and vomiting in one patient. This finding is not in 
correlation with the finding of other authors [13], 
where the majority of the reaction were delayed type.  
Sugars such as sorbitol, maltose, sucrose and 
glucose are added to some IVIG preparations as 
stabilisers which will prevent aggregate formation. 
However, there seems to be an association between 
these sugars and the development of acute renal 
failure or renal insufficiency in treated patients [6]. 
Sugar-stabilised solutions, such as IgVena and 
Octagam tend to have higher osmolality compared to 
the sugar-free preparations like Kiovig which is glycine 
stabilised. The hyperosmolar solutions may cause 
fluid shifts when given intravenously, and this may 
result in hemodynamic changes leading to infusion-
related adverse effects [6]. The sodium content of 
IVIG determines the osmolality of the infused solution, 
which in turn can affect tolerability and occurrence of 
adverse effects. Patients with hypertension and renal 
impairment may be affected by a high-sodium content 
solution. The IgA content of a solution is significant for 
patients with IgA deficiency. These patients are more 
likely to develop severe and sometimes fatal 
anaphylactic reactions [1]. The content of IgA varies 
among different IVIG preparations. However, using a 
preparation that is low in IgA does not guarantee an 
adverse reaction-free infusion. In our study, we were 
not able to determine reactions due to anti-IgA 
antibodies present in the patients because we don’t 
have laboratory tests for anti-IgA antibodies. 
These adverse reactions can be managed by 
slowing down the infusion rate and giving of 
medications such as antihistamines, paracetamol and 
corticosteroids, or switching the IVIG to different 
preparation. 
In conclusion, the ability to tolerate the effects 
of IVIG infusion without experiencing adverse effects 
varies from one person to another and from one IVIG 
preparation to another. The rate of infusion influences 
the occurrence of adverse reactions, as well as 
osmolality, sugar and IgA content of a preparation. In 
our study, 1.1% of patients given IVIG infusions 
experienced adverse events, which is less than the 
percentage of the reactions described in the literature. 
We speculate that the low rate of infusion which is 
preferable at our clinic is the main reason for less 
occurrence of adverse reactions, as well as the type 
of the immunoglobulins we used. In our study, most of 
the adverse effects occurred at the higher infusion 
rate of the IVIG preparation, but still in the 
recommended speed from the manufacturer. IVIG 
preparations differ in their composition and properties, 
and these can contribute to its efficacy and tolerability 
with some types showing a greater rate of adverse 
reactions than the others. Fever was the most 
common manifestation, followed by skin rash and 
chills. Symptoms occurred within 1 to 6 h from onset 
of infusion, were affected by fast infusion rates, and 
managed by reducing the rate of infusion and giving of 
medications such as paracetamol, antihistamines and 
steroids. 
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